A Widespread Respiratory Threat: RSV's Impact on New Jersey
Respiratory Syncytial Virus (RSV) is making headlines as it spreads across the nation, with New Jersey being no exception. This highly contagious virus is causing concern, especially among vulnerable populations. But here's where it gets controversial: while most people experience mild symptoms, RSV can lead to severe illness in certain groups, and this is the part most people miss.
According to the Centers for Disease Control and Prevention (CDC), RSV is a common virus that typically causes cold-like symptoms. However, it can pose a serious threat to infants, older adults, and those with compromised immune systems. In fact, RSV is the leading cause of childhood illness and hospitalization among infants.
The RSV season usually starts in the fall and peaks during winter. Data reveals a concerning trend in New Jersey, with emergency room visits and hospital admissions for RSV on the rise since October. Currently, over half of New Jersey's counties are reporting high or very high levels of RSV-related ER visits.
The latest CDC data shows that RSV accounts for a significant portion of emergency department visits, with 0.5% nationally and 0.7% in New Jersey. As of January 31, there have been 304 hospitalizations statewide, primarily among children under 4 and adults aged 65 and older.
The CDC reports that 2-3 out of every 100 infants under 6 months are hospitalized with RSV annually. While most children experience mild symptoms, those born prematurely or with certain medical conditions are at higher risk of severe illness. Sadly, between 100-300 children die from RSV each year, according to the CDC.
To protect infants from severe RSV, the CDC recommends a vaccine for pregnant women or an antibody treatment for the baby. These measures are crucial in preventing severe disease. The antibody treatment is unique; it injects monoclonal antibodies to prevent severe RSV in infants and some young children. There are two types available: clesrovimab and nirsevimab, both recommended for infants under 8 months during their first RSV season.
Public health experts also emphasize the importance of vaccination for adults aged 50-74 with chronic heart or lung disease, other chronic medical conditions, and those in long-term care facilities. Additionally, everyone aged 75 and older should consider vaccination.
One dose of the RSV vaccine provides protection for at least two years, according to the CDC. As of December 2025, vaccination coverage was 43.4% among adults aged 75 and older and 30.6% among those aged 50-74 at increased risk. These numbers highlight the need for continued awareness and education about RSV and its potential severity.
So, what's your take on this? Do you think enough is being done to raise awareness about RSV, especially among vulnerable populations? Share your thoughts in the comments below!
